Vir Biotechnology
166 hedge funds and large institutions have $3.64B invested in Vir Biotechnology in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 66 increasing their positions, 33 reducing their positions, and 29 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 33
54% more capital inflows, than outflows
Capital inflows: $172M | Capital outflows: $112M
42% more call options, than puts
Call options by funds: $29.3M | Put options by funds: $20.6M
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
6% more funds holding
Funds holding: 157 → 166 (+9)
0.01% less ownership
Funds ownership: 59.19% → 59.17% (-0.01%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pathway Capital Management
Irvine,
California
|
+$19.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$14.7M |
| 4 |
Millennium Management
New York
|
+$12.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$21.8M |
| 2 |
BlackRock
New York
|
-$13.8M |
| 3 |
MM
MWG Management
Road Town, Tortola,
British Virgin Islands
|
-$11.4M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$9.72M |
| 5 |
Natixis
Paris,
France
|
-$8.88M |
VIR Hedge Fund Activity: Q2 2021 in Review
166 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2021, worth a combined $3.64B — down 6.1% from $3.87B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new VIR positions and 29 closed out — a net gain of 10 holders — while 66 added to existing stakes and 33 trimmed.
The largest buyer was Pathway Capital Management, adding an estimated $19.3M. The largest seller was Goldman Sachs, cutting an estimated $21.8M.
- 166 institutional investors held Vir Biotechnology (VIR) as of Q2 2021, up from 157 in Q1 2021.
- Funds reported $3.64B of Vir Biotechnology stock for Q2 2021, down 6.1% quarter-over-quarter.
- 39 funds opened new Vir Biotechnology positions in Q2 2021 and 29 closed out, a net change of +10 holders.
- The largest Vir Biotechnology buyer in Q2 2021 was Pathway Capital Management, an estimated $19.3M added.
- The largest Vir Biotechnology seller in Q2 2021 was Goldman Sachs, an estimated $21.8M sold.
Based on aggregated 13F filings for Q2 2021.